AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06198075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
Study NCT05663242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Study NCT05663242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study NCT06223048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study NCT05239013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: 2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
Study NCT04306237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: IMB-1018972 200 mg tablet for oral administration
Study NCT04306237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matched placebo tablet for oral administration
Study NCT06394375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: OFA
Study NCT06394375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Given as analgesia in opioid balanced anesthesia (control) group
Study NCT04798118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: toilet bronchoscope
Description: Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
Study NCT04798118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: toilet bronchoscope
Description: Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
Study NCT05476107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-126
Description: Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
Study NCT05476107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
Study NCT05476107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radioactive Tablet (Part 2 Only)
Description: Single dose in two periods in Part 2 (optional)
Study NCT05043623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinoswab Junior
Description: Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
Study NCT05043623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined nose and throat swab
Description: Combined nose and throat swab (standard of care)
Study NCT05097248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: IV infusion, d1
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion, d1
Study NCT05097248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
Study NCT05097248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
Study NCT06517862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
Study NCT06517862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
Study NCT05066633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
Study NCT05066633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be in the form of identical tablets and will be administered orally once daily.
Study NCT05457348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planned incisions during phacoemulsification
Description: Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
Study NCT05457348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned incisions during phacoemulsification
Description: Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
Study NCT05043623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab
Study NCT05043623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbott Panbio™ COVID-19 antigen self-test kit
Description: COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, d1
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion, d1
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion, d1
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: IV infusion, d1
Study NCT05900921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: IV infusion, d1
Study NCT05035446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-incision plus one-port laparoscopic surgery
Description: The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
Study NCT05035446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional laparoscopic surgery
Description: It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
Study NCT05736094 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SURF
Description: Dual-frequency ultrasound
Study NCT05455580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurses Taking On Readiness Measures (N-TORM)
Description: The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
Study NCT05465954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT05465954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given IM
Study NCT05465954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05465954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05644002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puff Topography Biofeedback Training
Description: Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.
Study NCT05644002 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.
Study NCT05807568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCAEM EM-SART Pre-Screen
Description: Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
Study NCT05195489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Connectors
Description: The Family Connectors Program is a manualized program that uses a time-limited parent-to parent (i.e. peer parent) support and education program delivered by phone to families of youth with serious mental health difficulties, assisting family members in becoming fully engaged with provider teams who coordinate and provide care. Family Connectors is delivered weekly by phone over the course of between three and six months.
Study NCT06453239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pro-Neurotensin level as a Serum Biomarker
Description: Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
Study NCT05682313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elastography arm
Description: Renal ultrasound elastography to detect and classify the degree of fibrosis
Study NCT06225115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet
Study NCT06225115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet
Study NCT05689593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity ESWT Group
Description: ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
Study NCT05689593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity laser Group
Description: The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
Study NCT05689593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Control Group
Description: Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
Study NCT05689593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Control Group
Description: Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
Study NCT04310358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 short PLMs group 1
Description: Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
Study NCT05341570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-21668
Description: Subjects will receive BPI-21668 until disease progression
Study NCT05889351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel, 4 + 4 applications or 4 + 2 applications
Description: Control arm/placebo
Study NCT05889351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109 3% gel, 4 + 4 applications
Description: Cohort 1 active treatment
Study NCT05889351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109 3% gel, 4 + 2 applications
Description: Cohort 2 active treatment
Study NCT04310358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 short PLMs group 2
Description: Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
Study NCT05646329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
Study NCT05987917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-2
Description: Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
Study NCT05987917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: The subject who will serve as control will not be treated with the study device.
Study NCT05107349 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
Study NCT06676943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XEOS AURA 10 specimen PET-CT scan of tumour specimens
Description: Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
Study NCT05474911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
Study NCT05474911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound care
Description: The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
Study NCT05150834 — intervention group
Intervention type: OTHER
Intervention: This is observational study
Description: We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
Study NCT05270642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Thermal guided by Plan for Microwave Thermal Field system
Description: When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
Study NCT05045352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: echogenic needles for intravenous access
Description: echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
Study NCT05645770 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: ECG, computerized task
Description: ECG for cardiac waves computerized task for prospective memory
Study NCT05483582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study NCT05483582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study NCT05042934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo fine-needle aspiration
Study NCT05042934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV